Telix (TLX) news
Recent news
Telix Q2 revenue US$247M, strong momentum and pipeline progress
Telix Pharmaceuticals reported Q2 revenue of US$247 million, reflecting continued growth and operational progress in its therapeutic pipeline. The company noted strong momentum across its key programs, with several clinical trials advancing as planned. Management highlighted the importance of these…
AInvest Wire · Jul 20, 2026Telix Pharma sees FY revenue high end of $950M to $970M
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has raised its full-year (FY) 2025 revenue guidance to the upper end of its previously announced range, with revenue between $950-$970 million . This update reflects strong performance in the third quarter (Q3) of 2025, during which the company…
AInvest Wire · Jul 20, 2026Telix Pharmaceuticals Ltd Q2 group revenue US$247 million
AInvest Wire · Jul 20, 2026Telix Pharmaceuticals Ltd - Telix expects FY 2026 revenue and other income to be in excess of US$1 bln
AInvest Wire · Jul 20, 2026TLX 2Q '26 rev US$247M strong momentum pipeline progress
In the second quarter of 2026, TLX reported revenue of US$247 million, reflecting continued progress in its business pipeline and operational momentum [1]. The results indicate a stable performance amid evolving market conditions, with the company demonstrating consistent execution across its core…
AInvest Wire · Jul 20, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.